Cellectis S.A. (CLLS) Sees Large Decrease in Short Interest

Cellectis S.A. (NASDAQ:CLLS) was the target of a large drop in short interest in the month of October. As of October 13th, there was short interest totalling 515,344 shares, a drop of 24.2% from the September 29th total of 680,314 shares. Based on an average daily trading volume, of 88,279 shares, the days-to-cover ratio is currently 5.8 days. Approximately 1.5% of the shares of the stock are short sold.

Shares of Cellectis (CLLS) opened at 34.01 on Tuesday. Cellectis has a 52 week low of $16.09 and a 52 week high of $34.19. The firm’s market capitalization is $1.22 billion. The company’s 50 day moving average price is $28.93 and its 200-day moving average price is $28.88.

A number of institutional investors have recently modified their holdings of the business. Sphera Funds Management LTD. grew its holdings in Cellectis by 27.6% during the 2nd quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock worth $5,261,000 after acquiring an additional 44,100 shares during the period. Balyasny Asset Management LLC acquired a new stake in Cellectis during the 2nd quarter worth about $719,000. Eqis Capital Management Inc. grew its holdings in Cellectis by 27.2% during the 2nd quarter. Eqis Capital Management Inc. now owns 10,687 shares of the biotechnology company’s stock worth $276,000 after acquiring an additional 2,287 shares during the period. Wells Fargo & Company MN grew its holdings in Cellectis by 132.1% during the 2nd quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after acquiring an additional 5,435 shares during the period. Finally, Williams Jones & Associates LLC acquired a new stake in shares of Cellectis in the 2nd quarter valued at about $244,000. Hedge funds and other institutional investors own 14.82% of the company’s stock.

Several research firms recently commented on CLLS. SunTrust Banks, Inc. downgraded Cellectis from a “buy” rating to a “hold” rating and cut their target price for the stock from $35.00 to $20.00 in a research report on Tuesday, September 5th. Nomura cut their price objective on Cellectis from $49.00 to $43.00 and set a “buy” rating for the company in a research report on Wednesday, September 6th. Zacks Investment Research downgraded Cellectis from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Jefferies Group LLC reiterated a “buy” rating and issued a $47.00 price objective on shares of Cellectis in a research report on Tuesday, September 26th. Finally, BidaskClub downgraded Cellectis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $39.50.

TRADEMARK VIOLATION WARNING: “Cellectis S.A. (CLLS) Sees Large Decrease in Short Interest” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2017/10/31/cellectis-s-a-clls-sees-large-decrease-in-short-interest.html.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

What are top analysts saying about Cellectis S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cellectis S.A. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit